Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation

Area of Science:

• Immunology
• Transplantation Medicine
• Cellular Biology

Background:

• Calcineurin inhibitors and mTOR inhibitors are standard immunosuppressants for renal allograft recipients.
• These drugs can cause significant renal and extrarenal side effects.
• Belatacept presents a potential alternative with a different mechanism of action.

Purpose of the Study:

• To investigate the impact of switching from calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORIs) to Belatacept on T-cell immunophenotype.
• To assess changes in T-cell subsets, activation markers, and cytokine production post-Belatacept conversion.

Main Methods:

• Prospective study involving 8 renal allograft recipients.
• Flow cytometric immunophenotyping of T-cell subsets (naïve, memory, effector) and expression of CD28, CD25, CD69.
• Measurement of intracellular cytokines (IFN-gamma, IL-2) after stimulation.
• Analysis at multiple time points before and up to 12 months after Belatacept administration.

Main Results:

• No significant changes were observed in the percentage of T-cell subsets (central memory, naïve, effector memory, terminally differentiated effector memory).
• Expression of activation markers (CD28, CD25, CD69) on T-cells remained largely unchanged.
• Intracellular cytokine production (IFN-gamma, IL-2) after stimulation showed no significant alterations.

Conclusions:

• Conversion from CNIs or mTORIs to Belatacept appears to have no significant impact on the T-cell immunophenotype in kidney transplant recipients.
• Belatacept may offer an alternative immunosuppressive strategy without substantially altering T-cell dynamics.